BE2010C021I2 - - Google Patents

Info

Publication number
BE2010C021I2
BE2010C021I2 BE2010C021C BE2010C021C BE2010C021I2 BE 2010C021 I2 BE2010C021 I2 BE 2010C021I2 BE 2010C021 C BE2010C021 C BE 2010C021C BE 2010C021 C BE2010C021 C BE 2010C021C BE 2010C021 I2 BE2010C021 I2 BE 2010C021I2
Authority
BE
Belgium
Prior art keywords
fusion polypeptides
provides
traps
interleukin
antagonist
Prior art date
Application number
BE2010C021C
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BE2010C021I2 publication Critical patent/BE2010C021I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2010C021C 1998-09-25 2010-04-20 BE2010C021I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10185898P 1998-09-25 1998-09-25
US09/313,942 US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using
EP99952942A EP1115876B1 (fr) 1998-09-25 1999-09-22 Antagonistes a base de recepteurs, modes d'elaboration et d'utilisation

Publications (1)

Publication Number Publication Date
BE2010C021I2 true BE2010C021I2 (fr) 2018-12-04

Family

ID=26798712

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2010C021C BE2010C021I2 (fr) 1998-09-25 2010-04-20

Country Status (19)

Country Link
US (2) US6472179B2 (fr)
EP (3) EP1229047B1 (fr)
JP (1) JP3902728B2 (fr)
CN (1) CN100345970C (fr)
AT (2) ATE283365T1 (fr)
AU (1) AU758970C (fr)
BE (1) BE2010C021I2 (fr)
CA (1) CA2345109C (fr)
DE (3) DE69932832T2 (fr)
DK (1) DK1229047T3 (fr)
ES (2) ES2267300T3 (fr)
FR (1) FR10C0025I2 (fr)
HK (1) HK1045847B (fr)
IL (2) IL142103A0 (fr)
NO (2) NO329976B1 (fr)
NZ (1) NZ510720A (fr)
PL (1) PL201246B1 (fr)
PT (1) PT1229047E (fr)
WO (1) WO2000018932A2 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ATE272114T1 (de) * 1998-01-23 2004-08-15 Immunex Corp Rezeptoren für il-18
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2001092340A2 (fr) 2000-05-26 2001-12-06 Immunex Corporation Utilisation d'antagonistes vis-a-vis de l'interleukine-4 (il-4) et compositions correspondantes
US7446183B2 (en) 2000-06-16 2008-11-04 Asterion Limited Fusion protein comprising growth hormone and growth hormone receptor
EP2177616B1 (fr) * 2000-08-08 2012-02-29 ZymoGenetics, Inc. Récepteurs de cytokines zcytor 11 solubles
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US6846520B2 (en) * 2002-01-17 2005-01-25 Canon Kabushiki Kaisha Epoxy resin composition, surface treatment method, liquid-jet recording head and liquid-jet recording apparatus
JP2005525404A (ja) * 2002-05-01 2005-08-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｈｉｖ感染およびａｉｄｓを処置するためにサイトカインアンタゴニストを使用する方法
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
EP1578397B1 (fr) * 2002-11-15 2012-12-26 Genmab A/S Anticorps monoclonaux humains contre cd25
US6919012B1 (en) 2003-03-25 2005-07-19 Olimex Group, Inc. Method of making a composite article comprising a ceramic coating
DK1606318T3 (da) 2003-03-26 2009-11-02 Apogenix Gmbh Forbedrede Fc-fusionsproteiner
WO2004100987A2 (fr) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Procede d'utilisation d'antagonistes de l'il1 pour le traitement d'hyperplasie neointimale
WO2004098596A1 (fr) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprenant roflumilast et il-1 trap
BRPI0411248A (pt) * 2003-06-11 2006-07-25 Wyeth Corp método para produzir um polipeptìdeo
HUE029951T2 (en) * 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
CA2536936A1 (fr) * 2003-09-05 2005-03-17 National Research Council Of Canada Proteine hybride bispiralee avec domaines de recepteurs cellulaires
NZ547588A (en) 2003-11-07 2009-05-31 Immunex Corp Antibodies that bind interleukin-4 receptor
EP1723173B1 (fr) * 2004-02-27 2008-05-14 Regeneron Pharmaceuticals, Inc. Polypeptides specifiques d'il-4/il-13 et utilisations therapeutiques associees
AU2005249570B2 (en) 2004-06-04 2011-06-16 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat autoinflammatory disease
EP3489257A1 (fr) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Polypeptides du récepteur actrii, procédés et compositions
AU2005277357B2 (en) * 2004-08-17 2011-08-04 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
EP1630232B1 (fr) * 2004-08-27 2008-07-02 CONARIS research institute AG Séquences de nucléotides optimisées codant pour sgp130
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
CN101094688B (zh) * 2004-09-13 2013-05-01 建新公司 多聚构建体
MX2007004374A (es) * 2004-10-12 2008-01-29 Amprotein Corp Proteina quimerica.
EA015706B1 (ru) 2004-10-22 2011-10-31 Займоджинетикс, Инк. Моноклональное антитело или его фрагмент, связывающиеся с полипептидом il-22ra, гуманизированное антитело, полученное из указанного антитела, гибридомы, продуцирующие антитело, и применение указанного антитела
JP2008527981A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 治療目的および診断目的のためにパラメーターにより選択されたｇｍ−ｃｓｆ、ｉｌ−３、ｉｌ−４、ｉｌ−５、ならびにそのキメラ
HUE034109T2 (en) * 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
US7732167B2 (en) * 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
EP2295080A3 (fr) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC Réduction de lymphocytes B au moyen de molécules de liaison spécifique de CD37 et spécifique de CD20
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
WO2007061981A2 (fr) 2005-11-21 2007-05-31 Lumera Corporation Detecteur a resonance de plasmon en surface avec mecanisme de balayage d’angle entraine par actionneur
CN101370511B (zh) * 2005-11-23 2015-07-01 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP2781222B1 (fr) * 2005-11-23 2017-08-02 Acceleron Pharma, Inc. Antagonistes de l'activine-actriia destinés à être utilisés pour la promotion de la croissance osseuse
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
WO2007110205A2 (fr) 2006-03-24 2007-10-04 Merck Patent Gmbh Domaines de proteine heterodimerique d'ingenierie
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
ES2352561T3 (es) * 2006-06-30 2011-02-21 Conaris Research Institute Ag Dímeros de sgp 130fc mejorados.
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
AU2007279205B2 (en) 2006-07-28 2013-09-26 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
MX2009004051A (es) * 2006-10-20 2009-05-11 Regeneron Pharma Uso de antagonistas de il-1 para tratar gota y pseudo gota.
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5272735B2 (ja) * 2007-01-30 2013-08-28 国立大学法人 新潟大学 生物学的製剤
CA2677007A1 (fr) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Antagonistes de l'activine-actriia et leurs utilisations dans le traitement ou la prevention du cancer du sein
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2481415B1 (fr) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Compositions comprenant des antagonistes Activin-ActRIIA
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
EP2574671B1 (fr) 2007-03-19 2016-02-03 National Research Council Of Canada Antagonistes de ligands et leurs utilisations
WO2009010539A2 (fr) * 2007-07-19 2009-01-22 Ablynx. N.V. Recepteur de l'interleukine-6 (il-6) derive de macaca fascicularis
JP2010539236A (ja) 2007-09-18 2010-12-16 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
JP2011502163A (ja) * 2007-10-31 2011-01-20 ザ スクリプス リサーチ インスティテュート 持続性ウイルス感染を治療するための併用療法
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
WO2010031168A1 (fr) * 2008-09-17 2010-03-25 National Research Council Of Canada Agents de liaison hétéro-multivalents pour des membres de la superfamille des tgf-β
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
NZ627111A (en) 2008-11-26 2015-10-30 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
JP5912078B2 (ja) 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
EP3290439B1 (fr) 2009-06-12 2020-09-02 Acceleron Pharma Inc. Protéines de fusion actriib-fc tronquées
EP3332796A1 (fr) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Protéines actriib et variants et leurs utilisations se rapportant à l'induction de l'utrophine pour une thérapie de la dystrophie musculaire
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
CN103492416A (zh) 2011-04-15 2014-01-01 默克专利股份公司 用于癌症中使用的抗il-1r1抑制剂
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
BR112014015003A2 (pt) 2011-12-19 2019-09-24 Amgen Inc composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
EP2928916B1 (fr) * 2012-12-10 2019-03-13 Vib Vzw Nouveaux inhibiteurs interleukine-33
SG11201505960VA (en) 2013-02-01 2015-08-28 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
EP4050019A1 (fr) 2013-02-15 2022-08-31 R-Pharm International, LLC Composition d'inhibiteur d'il-1beta et utilisation correspondante
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
WO2016008975A1 (fr) 2014-07-18 2016-01-21 Sanofi Méthode de prédiction du résultat d'un traitement à l'aide d'aflibercept d'un patient suspecté d'être atteint d'un cancer
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
RS65665B1 (sr) 2014-12-01 2024-07-31 Ferring Bv Selektivne kompozicije inhibitora il-6-trans-signalizacije
EP3226888B1 (fr) 2014-12-01 2021-04-21 Ferring B.V. Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif
TWI730949B (zh) 2014-12-03 2021-06-21 美商西建公司 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
WO2016183222A1 (fr) * 2015-05-12 2016-11-17 Regeneron Pharmaceuticals, Inc. Détermination de la pureté de protéine multimère
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
AU2017336546C1 (en) 2016-09-27 2025-05-29 Epicentrx, Inc. Immunomodulatory fusion proteins
CA3059731A1 (fr) * 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Molecule recepteur d'il4/il13 a usage veterinaire
KR102757384B1 (ko) 2017-09-27 2025-01-20 에피센트알엑스, 인코포레이티드 면역조절 융합 단백질
TWI823906B (zh) 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
CN110950965B (zh) * 2018-09-26 2021-10-15 重庆精准生物技术有限公司 抗人cd123的嵌合抗原受体及其应用
TW202607038A (zh) 2020-10-19 2026-02-16 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
WO1991018982A1 (fr) * 1990-06-05 1991-12-12 Immunex Corporation Recepteurs de l'interleukine-1 de type ii
ATE169030T1 (de) * 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
EP0533006A1 (fr) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimères constituées du récepteur de l'interleukine 5 et de polypeptides d'immunoglobulines
EP0611302B1 (fr) * 1991-10-15 2000-03-29 MULLARKEY, Michael F. Recepteurs pour le traitement des troubles inflammatoires de phase tardive
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
DE69321720T2 (de) * 1992-03-09 1999-05-06 Ludwig Institute For Cancer Research, New York, N.Y. Für den interleukin-9-rezeptor kodierende nukleinsäuresequenzen bzw. dafür komplementäre nuleinsäuresequenzen
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
WO1993019163A1 (fr) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Genes de recepteurs chimeres et cellules transformees au moyen desdits genes
EP0670730B1 (fr) * 1992-03-30 2003-06-04 Immunex Corporation Proteine de fusion comprenant deux recepteurs du facteur de necrose tumorale
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
WO1994022914A1 (fr) * 1993-04-06 1994-10-13 Fred Hutchinson Cancer Research Center Recepteurs de cytokine chimeriques dans des lymphocytes
EP0716703A1 (fr) * 1993-09-03 1996-06-19 PRENDERGAST, Kenneth, Francis Compositions proteiques de fusion contenant la proteine de liaison a la glycophorine (gbp 130)
AU701623B2 (en) * 1993-10-14 1999-02-04 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
IL114825A0 (en) * 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
AU3830895A (en) 1994-10-07 1996-05-02 Amgen Boulder Inc. Dimeric il-4 inhibitors
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US5837816A (en) * 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU3668897A (en) * 1996-07-17 1998-02-09 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
WO1998008969A1 (fr) * 1996-08-26 1998-03-05 Human Genome Sciences, Inc. Molecule accessoire soluble du recepteur de l'interleukine 1
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
ATE272114T1 (de) * 1998-01-23 2004-08-15 Immunex Corp Rezeptoren für il-18

Also Published As

Publication number Publication date
CA2345109A1 (fr) 2000-04-06
JP2002525119A (ja) 2002-08-13
NO20011513D0 (no) 2001-03-23
ATE283365T1 (de) 2004-12-15
EP1229047A3 (fr) 2002-10-02
IL142103A (en) 2007-07-04
ES2233733T3 (es) 2005-06-16
AU758970B2 (en) 2003-04-03
EP1115876B1 (fr) 2006-08-16
FR10C0025I1 (fr) 2010-05-21
US20020164690A1 (en) 2002-11-07
DK1229047T3 (da) 2005-02-21
NO20011513L (no) 2001-05-25
ATE336583T1 (de) 2006-09-15
JP3902728B2 (ja) 2007-04-11
US6472179B2 (en) 2002-10-29
FR10C0025I2 (fr) 2011-04-01
NO2011003I1 (no) 2011-05-02
WO2000018932A3 (fr) 2000-11-02
EP1115876A2 (fr) 2001-07-18
AU758970C (en) 2007-05-03
CA2345109C (fr) 2012-12-18
NO2011003I2 (fr) 2011-04-11
HK1045847A1 (en) 2002-12-13
AU6499499A (en) 2000-04-17
HK1045847B (en) 2005-03-24
PL201246B1 (pl) 2009-03-31
DE69922269T2 (de) 2005-12-01
EP1405915A1 (fr) 2004-04-07
WO2000018932A9 (fr) 2000-08-31
IL142103A0 (en) 2002-03-10
DE69922269D1 (de) 2004-12-30
PT1229047E (pt) 2005-03-31
PL348529A1 (en) 2002-06-03
CN1357049A (zh) 2002-07-03
DE122010000023I2 (de) 2012-04-26
DE69932832D1 (de) 2006-09-28
NO329976B1 (no) 2011-01-31
HK1035377A1 (en) 2001-11-23
DE69932832T2 (de) 2007-02-08
ES2267300T3 (es) 2007-03-01
CN100345970C (zh) 2007-10-31
EP1229047A2 (fr) 2002-08-07
DE122010000023I1 (de) 2012-04-26
WO2000018932A2 (fr) 2000-04-06
US20020012962A1 (en) 2002-01-31
NZ510720A (en) 2003-11-28
EP1229047B1 (fr) 2004-11-24

Similar Documents

Publication Publication Date Title
FR10C0025I1 (fr)
DE69833670D1 (de) Homologe des tie-rezeptortyrosinekinase liganden
WO1996034107A3 (fr) Proteines antivirales, sequences d'adn codant pour ces proteines et utilisations
PT1015585E (pt) Homologos de ligandos de tie
PT1572967E (pt) Antagonistas baseados no receptor de il-1 e métodos de preparação e utilização
IL193886A0 (en) Antibodies that bind to ldcam sequences
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
SE9801455D0 (sv) New receptor
DK1009817T3 (da) RTD-receptor
PE20399A1 (es) Muteina ob
NZ512332A (en) Potassium channel interactors and uses therefor
WO2004007536A3 (fr) Nouvelles interactions de la proteine du virus d'epstein-barr ebna1, compositions et methodes associees
DK0938555T3 (da) Konstruktioner og komplekser af cyclin E
SE9604439D0 (sv) New receptor
NZ503852A (en) Death associated kinase containing ankyrin repeats (DAKAR)
DK1064389T3 (da) Sammensætninger med fusionsproteiner af kinase Wee1, nukleotidsekvenser, ekspressionssystemer og fremgangsmåder til deres anvendelse
SE0101700D0 (sv) Nucleotide sequences
WO2001066738A3 (fr) Acides nucleiques codant des polypeptides crsp1 humains et utilisations de ces derniers